Edition:
India

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

9.58USD
18 Jan 2018
Change (% chg)

-- (--)
Prev Close
$9.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
56,583
52-wk High
$15.65
52-wk Low
$6.38

Latest Key Developments (Source: Significant Developments)

Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER.SYNDAX PHARMACEUTICALS INC - NEW CLINICAL COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP.SYNDAX PHARMACEUTICALS - COS WILL EVALUATE COMBINATION OF CO'S ENTINOSTAT AND GENENTECH'S ATEZOLIZUMAB.SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED..SYNDAX PHARMACEUTICALS INC - GENENTECH WILL BE RESPONSIBLE FOR CONDUCTING TRIAL.SYNDAX PHARMACEUTICALS INC - TRIAL WILL BE CONDUCTED AS PART OF MORPHEUS, ROCHE'S NOVEL CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM.  Full Article

Syndax Pharmaceuticals reports Q3 loss per share $0.68
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update.Q3 loss per share $0.68.Q3 earnings per share view $-0.80 -- Thomson Reuters I/B/E/S.  Full Article

Syndax Pharma enters into license agreement with unit of Allergan
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Syndax Pharmaceuticals :On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing.Pursuant to agreement, co will make an upfront payment of $5.0 million to Allergan​.If parties commercialize Menin assets, co obligated to pay Allergan low single to low double-digit royalties on sales​.Under agreement, Allergan grants co worldwide license to portfolio of orally-available small molecule inhibitors of interaction of MLL protein​.Under agreement, may have to pay allergan up to $99 million in one-time development, regulatory milestone payments subject to achievement of milestones.In event of commercializing Menin assets, co to also pay up to $70 million in potential one-time sales-based milestone payments​.Company will be solely responsible for development and commercialization of Menin assets​.Under certain circumstances, co may be required to share a percentage of non-royalty income from sublicensees, with Allergan​.  Full Article

Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​.Syndax Pharmaceuticals Inc - ‍ entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, inc., a subsidiary of Allergan PLC​.  Full Article

Syndax Pharmaceuticals Q2 loss per share $0.47
Tuesday, 9 Aug 2016 

Syndax Pharmaceuticals Inc : Syndax Pharmaceuticals reports second quarter 2016 financial results and provides business update . Q2 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.47 .Progressing to phase 2 of ENCORE 601 in NSCLC and Melanoma.  Full Article

Syndax expands pipeline with license agreement for UCB6352
Wednesday, 6 Jul 2016 

Syndax Pharmaceuticals : Syndax expands pipeline with exclusive worldwide license agreement for UCB's colony stimulating factor 1 receptor (CSF-1R) antibody program .License deal for UCB6352, clinical trials to begin in 2016; cash, marketable securities sufficient to fund payment obligations.  Full Article

Syndax Pharmaceuticals posts Q1 loss per share of $2.85
Tuesday, 17 May 2016 

Syndax Pharmaceuticals Inc : Syndax Pharmaceuticals reports first quarter 2016 financial results and provides business update following IPO . Q1 loss per share $2.85 .Q1 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer

* SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER